Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Founded in 2002, VRS (VALUATION & RESEARCH SPECIALISTS) is an independent Financial Research & Consulting Firm with offices and presence in Athens and Luxembourg, and with senior presence in the broader European and North American markets, providing advanced equity research and valuation reports as well as value-related advisory services to local and international institutions, business entities and individual clients.
VRS is a boutique financial advisor with more than 15 years of experience in Corporate Valuation and Finance, and a diversified client base including some of the largest Companies in Greece.
Since 2002, VRS has completed more than 200 engagements in the areas of business valuation and financial analysis for more than 100 clients in a wide range of industries.
VRS has been honored to work with small and large private and publicly traded companies in Europe and overseas.
VRS provides corporations with services in financial restructuring, valuation of business enterprises, intangible assets and tangible fixed assets, value enhancement and strategic expansion.
VRS also assists companies involved in mergers and acquisitions and tracks the market in order to offer advice on when to make public offerings and private placements.
VRS cooperates with international organizations, banks and strategic or institutional investors.
VRS has worked with over 200 companies in Greece and internationally in financing, private placements, initial public offerings, business acquisitions and mergers.
BAYER - NEUTRAL | EUR81(+24%) Darolutamide not better than Xtandi in prostate cancer Significant improvement of free survival Darolutamide will have to compete with Xtandi We are less optimistic than Bayer regarding peak sales Neutral rating reiterated
Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.